With an initial €8 million (US$8.4 million) in seed funding in the bank, Tessellate Bio has emerged from stealth to tackle cancers that rely on the less well explored synthetic lethality mechanism of alternative lengthening of telomeres. Read More
A new degrader strategy has been previously proposed to mitigate platelet toxicity associated with Bcl-xL degraders. This strategy consists of selectively degrading Bcl-xL by the von Hippel-Lindau protein (VHL) E3 ligase in tumor cells, but not in platelets, which minimally express VHL. DT-2216 was developed as the first Bcl-xL degrader of this kind; however, this clinical candidate has still shown some platelet toxicity in vivo. Read More
Myeloproliferative neoplasms (MPNs) are a group of disorders of which the main hallmarks are bone marrow fibrosis and atypical megakaryocytes (MK) accumulation. Both Rho kinase (ROCK) and Aurora kinase (ARK) pathways are involved in correct MK maturation. Read More
Delix Therapeutics Inc. has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to support the advancement of DLX-007. Read More
Researchers at Albert-Ludwigs-Universität Freiburg and Deutsches Krebsforschungszentrum (DKFZ) have disclosed drug conjugates comprising fluorescent-labeled dye covalently linked to a radionuclide and a ligand targeting glutamate carboxypeptidase II (NAALADase; NAAG peptidase, FOLH1; PSMA) acting as positron-emission tomography (PET) and fluorescent imaging agents for diagnosis and treatment of prostate cancer. Read More
Ginkgo Bioworks Inc. has received a grant from the Bill & Melinda Gates Foundation to develop a novel cell-based technology for improving protein therapeutics delivery for patients in low- and middle-income countries. Read More
Simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) is considered a good strategy in cancer treatment, although current PI3K/HDAC dual inhibitors have limitations, such as low selectivity and moderate toxicity levels. Read More
Fibroblast activation protein (FAP) is a serine protease that is highly overexpressed in the stroma of most epithelial-derived tumors – including pancreatic, breast and colorectal cancers – in the context of cancer-associated fibroblasts (CAFs). Read More
Iecure Inc. has received clearance from the Australian Therapeutic Goods Administration (TGA) of the company’s clinical trial notification (CTN) for ECUR-506 (formerly GTP-506), an investigational therapy in development for the treatment of ornithine transcarbamylase (OTC) deficiency in pediatric (or neonatal) patients. Read More
Gilead Sciences Inc. has synthesized indoline compounds acting as viral replication inhibitors reported to be useful for the treatment of herpes simplex virus infection and herpes simplex virus encephalitis. Read More
CD33 is known to be highly expressed in myeloid cells and a good therapeutic target for treating acute myeloid leukemia (AML). In the search for more potent compounds, researchers from Dragonfly Therapeutics Inc. and Bristol Myers Squibb Inc. investigated the therapeutic potential of BMS-986357, also known as CC-96191. Read More
Vandria SA has announced a series A financing round raising $20.6 million (CHF18 million) to help advance its pipeline of first-in-class small-molecule mitophagy inducers. Read More
Researchers at Tufts University and University of Houston System have identified receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) and/or nucleotide-binding oligomerization domain-containing protein 2 (NOD2) inhibitors reported to be useful for the treatment of multiple sclerosis. Read More
Researchers from West China Hospital of Sichuan University presented data from a study that aimed to investigate the associations between serum cystatin C (CysC) levels and the progression and survival of patients with amyotrophic lateral sclerosis (ALS). Read More
Hangzhou Unogen Biotech Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of lymphoma. Read More
Yichang Humanwell Pharmaceutical Co. Ltd. has described quaternary ammonium salts reported to be useful for the treatment of anesthesia and pain. Read More
Encellin Inc. has announced the closing of a US$9.9 million financing round that will support the company’s development of its cell encapsulation platform with an initial focus on type 1 diabetes. Read More
Are you trying to stay on top of developments in CAR T therapies? Drug resistance? Emerging compounds? Updates from certain regulatory agencies? Want to be the first to learn about new biomarkers or business deals? You can still find these articles in the daily BioWorld e-newsletters or on the website, but if you’re laser-focused on a specific topic, we have a way to highlight the news you need as it happens, whether we’ve published a full-length feature story or a brief update. You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Happy holidays! Read More
.png?1670008839 "Acute myeloid leukemia")
